Mercury-induced amyloid-beta (Aβ) accumulation in the brain is mediated by disruption of Aβ transport

Journal of Toxicological Sciences

Volumn 39, Issue 4, 2014, Pages 625-635

  Kim, Dong Kyeong ^a   Park, Jung Duck ^a   Choi, Byung Sun ^a  

^a Chung Ang University College of Medicine   (South Korea)

Author keywords

Alzheimer's disease; Amyloid beta protein; Low density lipoprotein receptor related protein 1; Mercury; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; METHYLMERCURY; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; AMYLOID BETA-PROTEIN (1-42); ASPARTIC PROTEINASE; BACE PROTEIN, RAT; IMMUNOGLOBULIN RECEPTOR; METHYLMERCURY DERIVATIVE; PEPTIDE FRAGMENT; SECRETASE;

ADULT; ANIMAL CELL; ARTICLE; CAPILLARY ENDOTHELIUM; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; MALE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BLOOD; BRAIN; CEREBROSPINAL FLUID; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; WISTAR RAT;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; MALE; METHYLMERCURY COMPOUNDS; NEPRILYSIN; PEPTIDE FRAGMENTS; PROTEIN TRANSPORT; RATS, WISTAR; RECEPTORS, IMMUNOLOGIC;

EID: 84905042958     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.39.625     Document Type: Article

References (72)

1. Abd El-Aziz, G.S., El-Fark, M.M. and Saleh, H.A. (2012): The prenatal toxic effect of methylmercury on the development of the appendicular skeleton of rat fetuses and the protective role of vitamin E. Anat. Rec. (Hoboken.), 295, 939-949.
2. Adlard, P.A. and Buch, A.I. (2006): Metals and Alzheimer's disease. J. Alzheimers. Dis., 10, 145-163.
3. Agency for Toxic Substances and Disease Registry (ATSDR) (1999): Toxicological profile for mercury (update). US Dept of Health and Human Services, Atlanta. Alzheimer's Association (2013): Alzheimer's disease facts and figures. Alzheimers Dement., 9, 208-245.
4. Alzheimer's Disease International (ADI) (2013): World Alzheimer report. London.
5. Amadoruge, P.C. and Barnham, K.J. (2011): Alzheimer's disease and metals: a review of the involvement of cellular membrane receptors in metallosignalling. Int. J. Alzheimers Dis., 2011, Article ID 542043.
6. Andersen, C.L., Jensen, J.L. and Orntoft, T.F. (2004): Normalization of real-time quantitative reverse transcription-PCR data: a model- based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res., 64, 5245-5250.
7. Babusikova, E., Evinova, A., Jurecekova, J., Jesenak, M. and Dobrota, D. (2011): Alzheimer's Disease: Definition, Molecular and Genetic Factors, Advanced Understanding of Neurodegenerative Diseases, Dr Raymond Chuen-Chung Chang (Ed.), 3-28, InTech, Rijeka, Croatia.
8. Ballabh, P., Braun, A. and Nedergaard, M. (2004): The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis., 16, 1-13.
9. Barnham, K.J., Haeffner, F., Ciccotosto, G.D., Curtain, C.C., Tew, D., Mavros, C., Beyreuther, K., Carrington, D., Masters, C.L., Cherny, R.A., Cappai, R. and Bush, A.I. (2004): Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J., 18, 1427-1429.
10. Begley, D.J. and Brightman, M.W. (2003): Structural and functional aspects of the blood-brain barrier. Prog. Drug Res., 61, 39-78.
11. Bekris, L.M., Yu, C.E., Bird, T.D. and Tsuang, D.W. (2010): Genetics of Alzheimer disease. J. Geriatr. Psychiatry Neurol., 23, 213-227.
12. Berman, R.F., Pessah, I.N., Mouton, P.R., Mav, D. and Harry, J. (2008): Low-level neonatal thimerosal exposure: further evaluation of altered neurotoxic potential in SJL mice. Toxicol. Sci., 101, 294-309.
13. Blennow, K., Zetterberg, H. and Fagan, A.M. (2012): Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med., 2, a006221.
14. Budimir, A. (2011): Metal ions, Alzheimer's disease and chelation therapy. Acta Pharm., 61, 1-14.
15. Bush, A.I. (2008): Drug development based on the metals hypothesis of Alzheimer's disease. J. Alzheimers Dis., 15, 223-240.
16. Chen, M., Inestrosa, N.C., Ross, G.S. and Fernandez, H.L. (1995): Platelets are the primary source of amyloid beta-peptide in human blood. Biochem. Biophys. Res. Commun., 213, 96-103.
17. Choi, B.S. and Zheng, W. (2009): Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Res., 1248, 14-21.
18. Clarkson, T.W., Magos, L. and Myers, G.J. (2003): The toxicology of mercury--current exposures and clinical manifestations. N. Engl. J. Med., 349, 1731-1737.
19. de Souza, L.C., Chupin, M., Lamari, F., Jardel, C., Leclercq, D., Colliot, O., Lehericy, S., Dubois, B. and Sarazin, M. (2012): CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. Neurobiol. Aging., 33, 1253-1257.
20. Deane, R., Bell, R.D., Sagare, A. and Zlokovic, B.V. (2009): Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS. Neurol. Disord. Drug Targets, 8, 16-30.
21. Deane, R., Du, Y.S., Submamaryan, R.K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., Zhu, H., Ghiso, J., Frangione, B., Stern, A., Schmidt, A.M., Armstrong, D.L., Arnold, B., Liliensiek, B., Nawroth, P., Hofman, F., Kindy, M., Stern, D. and Zlokovic, B. (2003): RAGE mediates amyloidbeta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med., 9, 907-913.
22. Donahue, J.E., Flaherty, S.L., Johanson, C.E., Duncan, J.A.III, Silverberg, G.D., Miller, M.C., Tavares, R., Yang, W., Wu, Q., Sabo, E., Hovanesian, V. and Stopa, E.G. (2006): RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol., 112, 405-415.
23. Donnelly, P.S., Xiao, Z. and Wedd, A.G. (2007): Copper and Alzheimer's disease. Curr. Opin. Chem. Biol., 11, 128-133.
24. Epifanio, I. and Ventura-Campos, N. (2013): Hippocampal shape analysis in Alzheimer's disease using functional data analysis. Stat. Med. [Epub ahead of print]
25. Fossato da Silva, D.A., Teixeira, C.T., Scarano, W.R., Favareto, A.P., Fernandez, C.D., Grotto, D., Barbosa, F.Jr. and Kempinas, W.G. (2011): Effects of methylmercury on male reproductive functions in Wistar rats. Reprod. Toxicol., 31, 431-439.
26. Galasko, D., Chang, L., Motter, R., Clark, C.M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., Miller, B., Green, R., Basherad, R., Kertiles, L., Boss, M.A. and Seubert, P. (1998): High cerebrospinal fluid tau and low amyloidbeta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol., 55, 937-945.
27. Harada, M. (1995): Minamata disease: methylmercury poisoning in Japan caused by environmental pollution. Crit. Rev. Toxicol., 25, 1-24.
28. Hardy, J. and Selkoe, D.J. (2002): The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297, 353-356.
29. Herring, A., Yasin, H., Ambree, O., Sachser, N., Paulus, W. and Keyvani, K. (2008): Environmental enrichment counteracts Alzheimer's neurovascular dysfunction in TgCRND8 mice. Brain Pathol., 18, 32-39.
30. Hintelmann, H. (2010): Organomercurials. Their formation and pathways in the environment. Met. Ions. Life Sci., 7, 365-401.
31. Hock, C., Drasch, G., Golombowski, S., Muller-Spahn, F., Willershausen-Zonnchen, B., Schwarz, P., Hock, U., Growdon, J.H. and Nitsch, R.M. (1998): Increased blood mercury levels in patients with Alzheimer's disease. J. Neural. Transm., 105, 59-68.
32. Huang, X., Atwood, C.S., Moir, R.D., Hartshorn, M.A., Tanzi, R.E. and Bush, A.I. (2004): Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. J. Biol. Inorg. Chem., 9, 954-960.
33. Iverson, F., Downie, R.H., Paul, C. and Trenholm, H.L. (1973): Methyl mercury: acute toxicity, tissue distribution and decay profiles in the guinea pig. Toxicol. Appl. Pharmacol., 24, 545-554.
34. Jack, C.R.Jr., Petersen, R.C., Xu, Y.C., O'Brien, P.C., Smith, G.E., Ivnik, R.J., Boeve, B.F., Waring, S.C., Tangalos, E.G. and Kokmen, E. (1999): Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology, 52, 1397-1403.
35. Jin, X., Lok, E., Bondy, G., Caldwell, D., Mueller, R., Kapal, K., Armstrong, C., Taylor, M., Kubow, S., Mehta, R. and Chan, H.M. (2007): Modulating effects of dietary fats on methylmercury toxicity and distribution in rats. Toxicology, 230, 22-44.
36. Kim, D.K., Song, J.W., Park, J.D. and Choi, B.S. (2013a): Copper induces the accumulation of amyloid-beta in the brain. Mol. Cell. Toxicol., 9, 59-66.
37. Kim, N.Y., Ahn, S.J., Ryu, D.Y., Choi, B.S., Kim, H., Yu, I.J. and Park, J.D. (2013b): Effect of lifestyles on the blood mercury level in Korean adults. Hum. Exp. Toxicol., 32, 591-599.
38. Maler, J.M., Klafki, H.W., Paul, S., Spitzer, P., Groemer, T.W., Henkel, A.W., Esselmann, H., Lewczuk, P., Kornhuber, J. and Wiltfang, J. (2007): Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel Abeta species. Proteomics., 7, 3815-3820.
39. Martorana, A., Esposito, Z., Di, L.F., Giacobbe, V., Sancesario, G.M., Bucchi, G., Bonni, S., Bernardini, S., Sorge, R., Sancesario, G., Bernardi, G., Caltagirone, C. and Koch, G. (2012): Cerebrospinal fluid levels of Abeta42 relationship with cholinergic cortical activity in Alzheimer's disease patients. J. Neural Transm., 119, 771-778.
40. Mattson, M.P. (2003): Gene-diet interactions in brain aging and neurodegenerative disorders. Ann. Intern. Med., 139, 441-444.
41. Mattson, M.P. (2004): Pathways towards and away from Alzheimer's disease. Nature, 430, 631-639.
42. Mayeux, R. (2003): Epidemiology of neurodegeneration. Annu. Rev. Neurosci., 26, 81-104.
43. Mukherjee, A. and Hersh, L.B. (2002): Regulation of amyloid betapeptide levels by enzymatic degradation. J. Alzheimers Dis., 4, 341-348.
44. Mungas, D., Jagust, W.J., Reed, B.R., Kramer, J.H., Weiner, M.W., Schuff, N., Norman, D., Mack, W.J., Willis, L. and Chui, H.C. (2001): MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer's disease. Neurology, 57, 2229-2235.
45. National Research Council (NRC) (2000): Toxicological effects of methylmercury. Washington, DC: National Academy Press.
46. Olah, Z., Pakaski, M., Janka, Z. and Kalman, J. (2012): Marking the markers of Alzheimer's: too good to diagnose, too bad to use? Neuropsychopharmacol. Hung., 14, 165-176.
47. Olivieri, G., Brack, C., Müller-Spahn, F., Stähelin, H.B., Herrmann, M., Renard, P., Brockhaus, M. and Hock, C. (2000): Mercury induces cell cytotoxicity and oxidative stress and increases betaamyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells. J. Neurochem., 74, 231-236.
48. Pfaffl, M.W., Tichopad, A., Prgomet, C. and Neuvians, T.P. (2004): Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. Biotechnol. Lett., 26, 509-515.
49. Prelli, F., Castano, E.M., van Duinen, S.G., Bots, G.T., Luyendijk, W. and Frangione, B. (1988): Different processing of Alzheimer's beta-protein precursor in the vessel wall of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Biochem. Biophys. Res. Commun., 151, 1150-1155.
50. Preston, J.E., al-Sarraf, H. and Segal, M.B. (1995): Permeability of the developing blood-brain barrier to 14C-mannitol using the rat in situ brain perfusion technique. Brain Res. Dev. Brain Res., 87, 69-76.
51. Quinn, K.A., Grimsley, P.G., Dai, Y.P., Tapner, M., Chesterman, C.N. and Owensby, D.A. (1997): Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. J. Biol. Chem., 272, 23946-23951.
52. Ringman, J.M., Schulman, H., Becker, C., Jones, T., Bai, Y., Immermann, F., Cole, G., Sokolow, S., Gylys, K., Geschwind, D.H., Cummings, J.L. and Wan, H.I. (2012): Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch. Neurol., 69, 96-104.
53. Rosen, C., Andreasson, U., Mattsson, N., Marcusson, J., Minthon, L., Andreasen, N., Blennow, K. and Zetterberg, H. (2012): Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimer's disease. Neuromolecular. Med., 14, 65-73.
54. Rosen, C., Hansson, O., Blennow, K. and Zetterberg, H. (2013): Fluid biomarkers in Alzheimer's disease - current concepts. Mol. Neurodegener., 8, 20.
55. Sagare, A.P., Deane, R., Bell, R.D., Johnson, B., Hamm, K., Pendu, R., Marky, A., Lenting, P.J., Wu, Z., Zarcone, T., Goate, A., Mayo, K., Perlmutter, D., Coma, M., Zhong, Z. and Zlokovic, B.V. (2007): Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med., 13, 1029-1031.
56. Sagare, A.P., Deane, R., Zetterberg, H., Wallin, A., Blennow, K. and Zlokovic, B.V. (2011): Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-beta is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. J. Alzheimers Dis., 24, 25-34.
57. Salin, P., Castle, M., Kachidian, P., Barroso-Chinea, P., López, I.P., Rico, A.J., Kerkerian-Le Goff, L., Coulon, P. and Lanciego, J.L. (2008): High-resolution neuroanatomical tract-tracing for the analysis of striatal microcircuits. Brain Res., 1221, 49-58.
58. Selkoe, D.J. and Schenk, D. (2003): Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol., 43, 545-584.
59. Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, C., Mccormack, R., Wolfert, R., Selkoe, D., Liberburg, I. and Schenk, D. (1992): Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature, 359, 325-327.
60. Shibata, M., Yamada, S., Kumar, S.R., Calero, M., Bading, J., Frangione, B., Holtzman, D.M., Miller, C.A., Strickland, D.K., Ghiso, J. and Zlokovic, B.V. (2000): Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest., 106, 1489-1499.
61. Shirotani, K., Tsubuki, S., Iwata, N., Takaki, Y., Harigaya, W., Maruyama, K., Kiryu-Seo, S., Kiyama, H., Iwata, H., Tomita, T., Iwatsubo, T. and Saido, T.C. (2001): Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J. Biol. Chem., 276, 21895-21901.
62. Strozyk, D., Blennow, K., White, L.R. and Launer, L.J. (2003): CSF Abeta 42 levels correlate with amyloid-neuropathology in a population- based autopsy study. Neurology, 60, 652-656.
63. Sunderland, T., Linker, G., Mirza, N., Putnam, K.T., Friedman, D.L., Kimmel, L.H., Bergeson, J., Manetti, G.J., Zimmermann, M., Tang, B., Bartko, J.J. and Cohen, R.M. (2003): Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA, 289, 2094-2103.
64. Tapiola, T., Alafuzoff, I., Herukka, S.K., Parkkinen, L., Hartikainen, P., Soininen, H. and Pirttila, T. (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer- type pathologic changes in the brain. Arch. Neurol., 66, 382-389.
65. Teipel, S.J., Grothe, M., Lista, S., Toschi, N., Garaci, F.G. and Hampel, H. (2013): Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Med. Clin. North Am., 97, 399-424.
66. Ujiie, M., Dickstein, D.L., Carlow, D.A. and Jefferies, W.A. (2003): Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation, 10, 463-470.
67. von Arnim, C.A., Kinoshita, A., Peltan, I.D., Tangredi, M.M., Herl, L., Lee, B.M., Spoelgen, R., Hshieh, T.T., Ranganathan, S., Battey, F.D., Liu, C.X., Bacskai, B.J., Sever, S., Irizarry, M.C., Strickland, D.K. and Hyman, B.T. (2005): The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J. Biol. Chem., 280, 17777-17785.
68. Wang, Y., Goodrich, J.M., Werner, R., Gillespie, B., Basu, N. and Franzblau, A. (2012): An investigation of modifying effects of single nucleotide polymorphisms in metabolism-related genes on the relationship between peripheral nerve function and mercury levels in urine and hair. Sci. Total Environ., 417-418, 32-38.
69. Yamada, K., Hashimoto, T., Yabuki, C., Nagae, Y., Tachikawa, M., Strickland, D.K., Liu, Q., Bu, G., Basak, J.M., Holtzman, D.M., Ohtsuki, S., Terasaki, T. and Iwatsubo, T. (2008): The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells. J. Biol. Chem., 283, 34554-34562.
70. Yan, R., Bienkowski, M.J., Shuck, M.E., Miao, H., Tory, M.C., Pauley, A.M., Brashier, J.R., Stratman, N.C., Mathews, W.R., Buhl, A.E., Carter, D.B., Tomasselli, A.G., Parodi, L.A., Heinrikson, R.L. and Gurney, M.E. (1999): Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature., 402, 533-537.
71. Yoshida, M., Shimada, E., Arai, F. and Yamamura, Y. (1980): The relation between mercury levels in brain and blood or cerebrospinal fluid (CSF) after mercury exposure. J. Toxicol. Sci., 5, 243-250.
72. Zlokovic, B.V. (2004): Clearing amyloid through the blood-brain barrier. J. Neurochem., 89, 807-811.